Study of Treatment and Support Pathways for Adolescents with Depression in Finnish Schools
Evaluating Interpersonal Counseling Compared to Usual Care and No Treatment
Led by Finnish Institute for Health and Welfare · Updated on 2025-08-19
9000
Participants Needed
4
Research Sites
708 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a prospective observational cohort study in Finland to evaluate adolescent depression treatment pathways in primary care. The study focuses on adolescents aged 13 to 16 years attending grades 7 to 9 in selected schools, aiming to understand access to treatment and identify those who may benefit from adolescent interpersonal counseling IPC-A. The study compares IPC-A, a brief behavioral intervention, to treatment as usual and no treatment, assessing effectiveness and cost-effectiveness.
The study involves adolescents completing surveys over six months about depressive symptoms, treatment motivation, and benefits or harms from treatment every two weeks. Caretakers will also provide information on adolescent support needs and treatment outcomes through surveys at six-month intervals. When applicable, professionals providing support will report on their training and treatment content. Register data on social welfare and health care service use will be collected from one year before to up to ten years after the study to inform cost and service provision.
Participants will be followed for 12 months to measure outcomes including the proportion referred to specialized psychiatric services and changes in depression symptom scores. Data on received support and treatment response will be gathered from adolescents, caretakers, professionals, and patient records. The study will monitor benefits and harms of treatment, aiming to improve detection, equal access, and inform prevention strategies for adolescent depression.
CONDITIONS
Brief Title
Adolescent Interpersonal Counseling in Primary Care
Research Team
O
Outi Linnaranta, MD, PhD
J
Jasmin Kaljadin, MSc
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Adolescents attending grades 7 to 9 in selected schools
Aged between 13 and 16 years
Informed consent obtained
You will not qualify if you...
Received psychiatric care or psychosocial intervention in the 12 months before baseline
Unable to reliably understand Finnish, Plain Finnish, Swedish, or English for survey participation
Adolescent's or caretaker's report of a medical condition requiring acute treatment or support
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote)
Monitoring
Duration - 6 months
Participants are observed over 6 months to evaluate depressive symptoms and need for support through repeated assessments.
Multiple assessments over 6 months
Outpatient Treatment
Duration - Up to 6 months
Participants with sustained depression may receive interpersonal counseling (3 to 8 sessions), treatment as usual, or no treatment based on their needs and preferences.
3 to 8 therapy sessions depending on intervention
Long-term Monitoring
Duration - Up to 12 months and longer follow-up up to 10 years
Participants are followed for up to 12 months and beyond to track use of psychiatric and social services and changes in depression symptoms.
Periodic surveys and registry data collection up to 10 years
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Trial of 40 Hz Light Neurostimulation Therapy to Treat Major Depressive Disorder
Evaluating 5-hydroxytryptophan and Creatine Supplements to Enhance Antidepressant Treatment in Adults with Major Depressive Disorder Using Brain Imaging and Serotonin Measures
Randomized Study Evaluating a Single Oral Dose of CYB003 to Understand Brain and Symptom Changes in Adults With Major Depressive Disorder and Anxiety
Phase 2 Study on the Safety and Effectiveness of Zelquistinel Compared to Placebo for Treating Major Depressive Disorder in Adults Aged 18 to 64
Evaluating Oral DT120 Compared to Placebo in Adults With Major Depressive Disorder
A 12-Week Double-Blind Study Followed by a 40-Week Open-Label Extension
Psilocybin and Brain Activity Changes in Adults With Depression A Randomized Neuroimaging Study
Evaluating Vortioxetine for Major Depressive Disorder in Japanese Teens Aged 12 to 17 Using Daily Oral Tablets Compared to Placebo
Phase 2 Study of Oral Icalcaprant for Treating Major Depressive Disorder in Adults Aged 18 to 65
Evaluating Valbenazine for Adults With Tardive Dyskinesia Experiencing Symptoms During or After VMAT2 Inhibitor Treatment
Randomized Study Comparing AXS-05 and Bupropion for Preventing Relapse in Major Depressive Disorder
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Did national implementation of interpersonal counseling improve adolescent depression treatment pathways in primary care? Protocol for a longitudinal cohort study.